Novo Nordisk CSO Outlines Next Diabetes Challenges
This article was originally published in Scrip
Executive Summary
Novo Nordisk, market leader for diabetes therapies, released data fora number of its products at the recent European Association for the Study of Diabetes meeting, but the company is still striving for domination of the entire diabetes spectrum, Mads Krogsgaard Thomsen, executive vice-president and chief science officer at Novo Nordisk, told Scrip in an exclusive interview on the side lines of the event.
You may also be interested in...
Six New Molecules By 2030 – J&J’s Neuroscience Strategy
Can neuroscience be precise? Peter Fang, worldwide VP of neuroscience, explains J&J's approach to precision medicine in Alzheimer’s disease, depression and other neurological conditions.
Accessing Venture Debt From The EIB
Tips from Gergely Krajcsi, senior investment officer at the European Investment Bank, on how biotechs can access loans for faster growth.
In Vivo's 2024 Rising Leaders At A Glance
Top 30 leaders: see the list of industry influencers highlighted in the fifth edition of In Vivo's Rising Leaders series.